CV Trials For Symptomatic Conditions Feasible But Not Always Practical, FDA Panel Says
FDA committee members generally reject the notion that dedicated safety studies are not possible for peripherally active mu opioid receptor antagonists in chronic pain patients, but acknowledge a low background cardiovascular risk and symptomatic nature of opioid-induced constipation make such trials problematic. The advisors’ opinions on the practicality of such trials in low-risk patients with symptomatic conditions could have implications beyond PAMORAs.
You may also be interested in...
FDA already issued a warning based on preliminary data from the CARES outcomes study, but now the final results of the confirmatory trial are in and show higher risk for cardiovascular death for Uloric compared with generic allopurinol.
Policy of continuing safety trials into the post-approval setting gets favorable description in FDA meeting announcement, but delay of Contrave application suggests Orexigen may need to launch a new trial.
Agency grants Salix/Progenics’ appeal seeking a chronic use indication for the mu opioid receptor antagonist without the need for additional clinical data on cardiovascular safety pre-approval. Decision also bodes well for AstraZeneca’s Movantik, which has a September user fee deadline.